Phase 3 N=103 Altitude Sickness Prevention and Efficacy of Comparative Treatments
Acute Mountain Sickness
Primary: Number of Participants With Acute Mountain Sickness — 24; 22; 15 Count of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=130 Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing
Prophylaxis of Acute Mountain Sickness
Primary: Number of Participants With Acute Mountain Sickness as Measured by the Lake Louise Score — 21; 21 Participants
Phase 4 N=99 Three New Ideas to Protect Special Forces From the Stress of High Altitude
Mountain Sickness
Primary: Change in Environmental Symptoms Questionnaire at High Altitude — 0.132; 0.122; 0.080; 0.069 score on a scale
Phase 2 N=41 Rapid Acclimatization to Hypoxia at Altitude
Physiological Function in Low Oxygen Environment
Primary: Magnitude of Decrement in Exercise Time Trial Performance in Hypoxia (Low Oxygen) Compared With Normoxia (Normal Oxygen). — 22.3; 25.2; 22.2; 24.0 minutes
Phase 3 N=28 Drug Combination on Exercise Performance at High Altitude
Acute Mountain Sickness
Primary: Time (Minutes) to Complete 2 Miles on a Treadmill — 1544; 1540 seconds
N/A N=219 Study Looking at End Expiratory Pressure for Altitude Illness Decrease (SLEEP-AID)
Acute Mountain Sickness
Primary: Incidence of Acute Mountain Sickness — 18; 16 Participants
Phase 3 N=89 Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS)
Altitude Sickness
Primary: Acute Mountain Sickness — 19; 26 Participants
N/A N=23 The Effect of Chronic Nitrate Supplementation on Acute Mountain Sickness and Exercise Performance in Hypoxia
Hypoxia
Primary: Acute Mountain Sickness (AMS-C) as Assessed by the Environmental Symptoms Questionnaire. — 0.36; 0.21 scores on a scale
Phase 2 N=18 Sildenafil for Swimming-Induced Pulmonary Edema (SIPE) Prevention
Edema, Pulmonary · Immersion · Diving
Primary: Number of Participants With Pulmonary Edema — 7; 9 Participants — p=0.317
Phase 4 N=22 Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude
Hypertension, Pulmonary · Altitude Sickness
Primary: Mean Pulmonary Artery Pressure — 16.8667; 15.6545; 16.3800; 16.6833 mm Hg
Phase 4 N=81 Pseudoephedrine Prophylaxis for Prevention of Middle Ear Barotrauma in Hyperbaric Oxygen Therapy
Barotrauma;Ear
Primary: Requirement of Oxymetalozine Rescue for Ear Pain During Hyperbaric Therapy Compression — 8; 11 Participants
Phase 2 N=12 Evaluation of the Attenuation by Aes-103 of Hypoxia Mediated Decrements in Endurance Exercise Performance
Hypoxia
Primary: Primary Objective Endurance Exercise Performance — 22.4; 24.5; 24.0; 24.6 minutes
Phase 4 N=581 Chemoprophylaxis Plus Early Ambulation
Pulmonary Embolism · Thoracic Surgery
Primary: Incidence of Postoperative Pulmonary Embolism (PE) in Surgical Thoracic Patients Under Currently Used PE Prevention Strategies. — 3 Participants
Phase 1 N=22 DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria
Plasmodium Falciparum, Malaria
Primary: Infection Rate — 5; 6; 3; 0 Participants
Phase 3 N=108 A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis
Migraine
Primary: Pain Relief (PR) — 105; 21; 88; 72 Attacks — p=<0.001
Phase 4 N=55 Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine
Migraine
Primary: Number of Migraine Attacks in Participants Using Frovatriptan in a Preemptive Treatment Paradigm vs. Daily Topiramate — 1.35; 2.12 Migraine attacks
Phase 3 N=400 Low Doses of Aspirin in the Prevention of Preeclampsia
Preeclampsia
Primary: Incidence of Preterm (<37 Weeks) Preeclampsia — 22; 16 Participants — p=0.28
Phase 3 N=702 Study of APD421 as PONV Treatment (Prior Prophylaxis)
Postoperative Nausea and Vomiting
Primary: Number of Participants With Complete Response (Success of Initial PONV Treatment) — 80; 96; 67 Participants — p=0.003
Phase 4 N=83 Azithromycin in Bronchiolitis Obliterans Syndrome
Bronchiolitis Obliterans Syndrome · Graft Rejection · Lymphocytic Bronchiolitis
Primary: Prevalence of Bronchiolitis Obliterans Syndrome (BOS) — 5; 19 participants
Phase 1 N=16 Safety Evaluation of Aminophylline and Methazolamide
Mountain Sickness
Primary: Adverse Events. — 29; 40 Events
Phase 4 N=39 Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine
Migraine
Primary: Percent Change of Headache Days Compared to Baseline — -13.50; -36.50 percent change of headache days
N/A N=11,976 Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Premature Birth
Primary: Incidence of Preterm Birth — 668; 754 Participants — p=0.012
Phase 3 N=1,483 Pre-exposure Prophylaxis for SARS-Coronavirus-2
COVID-19 · Corona Virus Infection · ARDS
Primary: COVID-19-free Survival — 464; 468; 454 Participants
Phase 3 N=473 Treatment of Multiple Attacks of Acute Migraine (0462-025)
Migraine Headache
Primary: Pain Relief at 2 Hours During the First Migraine Attack Period — 246; 30; 74; 52 participants
Phase 3 N=34 Metformin for the Prevention of Episodic Migraine (MPEM)
Migraine
Primary: Headache Days — 23.64; 24.33 Days — p=0.83
Phase 4 N=27 Effects of Nebivolol Versus Carvedilol on Cardiopulmonary Function at High Altitude in Healthy Subjects.
Hypoxia · Altitude · Heart Failure
Primary: Peak Exercise Oxygen Consumption — 33.9; 37.6; 38.0; 33.9 ml/Kg/min — p=0.01
Phase 2 N=526 Prevention Study in Adult Patients Suffering From Migraine Headaches
Migraine Disorders · Migraine
Primary: Adjusted Mean Change From Baseline in the Number of Migraine Headache Days (MHD) During the Last 4 Weeks of Treatment Prior to Taper — -3.8; -3.6; -3.8; -3.3 Migraine…
N/A N=1,499 Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on ART in Malawi
HIV
Primary: Severe Events — 3.3; 4.2; 4.2 Events per 100 participant-years — p=<=0.05
Phase 3 N=560 Study of APD421 as PONV Treatment (no Prior Prophylaxis)
Postoperative Nausea and Vomiting
Primary: Complete Response (Success of Initial PONV Treatment) — 60; 59; 39 Participants — p=0.016
Phase 4 N=11 Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia
Hypoxia, Altitude
Primary: Performance Time — 17.03; 18.08; 16.32 minutes — p=0.047